MarketCap
Facebook
X
TelegramQuarterly report 2024-Q1
added 05-14-2024
Acorda Therapeutics Operating Cycle 2011-2026 | ACOR
Annual Operating Cycle Acorda Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 394 | 236 | 264 | 361 | 306 | 125 | 151 | 182 | 167 | 151 | 177 | 164 | 184 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 394 | 125 | 220 |
Quarterly Operating Cycle Acorda Therapeutics
| 2024-Q1 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 381 | 417 | - | 166 | 195 | 314 | - | 198 | 258 | 273 | - | 250 | 448 | 709 | 39.9 | 330 | 285 | 328 | 30.9 | 120 | 101 | 192 | 39.4 | 52.7 | 53.3 | 51.1 | - | 35.1 | 37.4 | 33 | - | 19.4 | 25.2 | 29.1 | - | 27.7 | 30.3 | 35.7 | - | 33.1 | 32.3 | 36.3 | - | 31 | 31.8 | 31.5 | - | 22.4 | 31.9 | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 709 | 19.4 | 144 |
Operating Cycle of other stocks in the Biotechnology industry
| Issuer | Operating Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Altimmune
ALT
|
15.1 K | $ 4.2 | -2.67 % | $ 298 M |  USA |
 |
Apellis Pharmaceuticals
APLS
|
115 | $ 20.24 | -3.44 % | $ 2.55 B | USA |
 |
Aptorum Group Limited
APM
|
4.89 | $ 0.8 | 1.87 % | $ 4.36 M |  China |
 |
Aptevo Therapeutics
APVO
|
191 | $ 7.2 | -1.64 % | $ 1.99 M | USA |
 |
I-Mab
IMAB
|
271 | - | - | $ 866 M | China |
 |
Aquestive Therapeutics
AQST
|
181 | $ 4.1 | 2.37 % | $ 356 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
12.8 | - | - | $ 40.3 B | USA |
 |
AgeX Therapeutics
AGE
|
78.4 | - | -10.17 % | $ 12.2 K | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
43.2 | $ 8.35 | 1.46 % | $ 225 M |  Israel |
 |
Ardelyx
ARDX
|
1.05 K | $ 6.37 | -2.75 % | $ 1.54 B | USA |
 |
Arcutis Biotherapeutics
ARQT
|
291 | $ 25.33 | -6.1 % | $ 3.22 B | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
32 | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
245 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Arvinas
ARVN
|
4.66 | $ 12.97 | -2.3 % | $ 920 M | USA |
 |
Arrowhead Pharmaceuticals
ARWR
|
8.75 | $ 61.74 | -2.42 % | $ 8.26 B | USA |
 |
Atossa Therapeutics
ATOS
|
249 | $ 4.39 | -0.9 % | $ 553 M | USA |
 |
Atara Biotherapeutics
ATRA
|
50.4 | $ 5.01 | -7.47 % | $ 37.5 M | USA |
 |
Aurinia Pharmaceuticals
AUPH
|
659 | $ 14.14 | -0.21 % | $ 1.9 B |  Canada |
 |
Acasti Pharma
ACST
|
1.97 | - | 4.01 % | $ 150 M | Canada |
 |
Институт стволовых клеток человека
ISKJ
|
104 | - | - | - |  Russia |
 |
AIkido Pharma
AIKI
|
17.9 | - | 1.93 % | $ 17.4 M | USA |
 |
Albireo Pharma
ALBO
|
40.8 | - | -0.23 % | $ 916 M | USA |
 |
Axon Enterprise
AXON
|
116 | $ 570.5 | 5.18 % | $ 43.2 B | USA |
 |
Axsome Therapeutics
AXSM
|
273 | $ 162.28 | -0.98 % | $ 8.07 B | USA |
 |
Aytu BioScience
AYTU
|
360 | $ 2.56 | -0.58 % | $ 16.1 M | USA |
 |
Alpine Immune Sciences
ALPN
|
154 | - | - | $ 2.17 B | USA |